Results 11 to 20 of about 234 (145)

S-Amlodipine: An Isomer with Difference—Time to Shift from Racemic Amlodipine [PDF]

International Journal of Hypertension, 2018
Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal.
Jamshed Dalal, J. C. Mohan, S. S. Iyengar, Jagdish Hiremath, Immaneni Sathyamurthy, Sandeep Bansal, Dhiman Kahali, Arup Dasbiswas   +7 more
doaj   +4 more sources

S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial [PDF]

Trials, 2018
Background The efficacy of a combination of a calcium channel blocker (CCB) plus chlorthalidone (diuretic) versus a CCB plus an angiotensin receptor blocker (ARB) in patients not responding to CCB monotherapy has not been evaluated previously. We plan to
Sang-Ho Jo, Sung-Ji Park, Eung Ju Kim, Soo-Joong Kim, Hyun-Jae Cho, Jong-Min Song, Jinho Shin, Jin Joo Park, Joon-Han Shin, Kyoo-Rok Han, Dong-Ju Choi   +10 more
doaj   +3 more sources

Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects

Drug Design, Development and Therapy, 2018
Woo Youl Kang,1,2,* Sook Jin Seong,1,* Boram Ohk,1,2 Mi-Ri Gwon,1,3 Bo Kyung Kim,1,2 Sookie La,4 Hyun-Ju Kim,3 Seungil Cho,1 Young-Ran Yoon,1,2 Dong Heon Yang,5 Hae Won Lee1 1Clinical Trial Center, Kyungpook National University Hospital, Daegu, Republic
Kang WY, Seong SJ, Ohk B, Gwon M, Kim BK, La S, Kim HJ, Cho S, Yoon Y, Yang DH, Lee HW   +10 more
doaj   +6 more sources

S-amlodipine induces liver inflammation and dysfunction through the alteration of intestinal microbiome in a rat model

Gut Microbes
S-amlodipine, a commonly prescribed antihypertensive agent, is widely used in clinical settings to treat hypertension. However, the potential adverse effects of long-term S-amlodipine treatment on the liver remain uncertain, given the cautionary ...
Xinxin Liu, Hui Fang, Liuzhu Pan, Peng Zhang, Huai Lin, Huihui Gao, Chaolin Ye, Daqing Mao, Yi Luo   +8 more
doaj   +3 more sources

Efficacy and safety of two fixed-dose combinations of S-amlodipine and telmisartan (CKD-828) versus S-amlodipine monotherapy in patients with hypertension inadequately controlled using S-amlodipine monotherapy: an 8-week, multicenter, randomized, double-blind, Phase III clinical study

Drug Design, Development and Therapy, 2016
Sang-Hyun Ihm,1 Hui-Kyung Jeon,1 Tae-Joon Cha,2 Taek-Jong Hong,3 Sang-Hyun Kim,4 Nae-Hee Lee,5 Jung Han Yoon,6 Namsik Yoon,7 Kyung-Kuk Hwang,8 Sang-Ho Jo,9 Ho-Joong Youn1 1Division of Cardiology, Department of Internal Medicine, The Catholic ...
Ihm SH, Jeon HK, Cha TJ, Hong TJ, Kim SH, Lee NH, Yoon JH, Yoon NS, Hwang KK, Jo SH, Youn HJ   +10 more
doaj   +6 more sources

Development and Evaluation of a Modified Fixed-Dose Combination Antihypertensive Tablet Containing S-Amlodipine Besylate: A Bioequivalence and Stability Study

Pharmaceutics
Background/Objectives: Fixed-dose combination (FDC) antihypertensive medications containing olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide are widely used for the treatment of essential hypertension.
Hyeon Woo Moon, Jin-Hyuk Jeong, Chun-Woong Park   +2 more
doaj   +3 more sources

Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers

Drug Design, Development and Therapy, 2017
Minkyung Oh,1,2,* Sung-Eun Park,3,* Jong-Lyul Ghim,1–3 Young-Kyung Choi,1 Eon-Jeong Shim,1–3 Jae-Gook Shin,1–3 Eun-Young Kim1–3 1Department of Pharmacology, 2PharmacoGenomics Research Center, Inje University College of Medicine ...
Oh M, Park SE, Ghim JL, Choi YK, Shim EJ, Shin JG, Kim EY   +6 more
doaj   +6 more sources

S-AMLODIPINE AS A MODERN EFFECTIVE ANTIHYPERTENSIVE AND AN ANTIANGINAL AGENT

Wiadomości Lekarskie, 2023
The aim: Study of the clinical and hemodynamic effects of S-amlodipine in patients with arterial hypertension associated with coronary artery disease, in individuals with preserved LV systolic function. Materials and methods: The study includes 51 patients with arterial hypertension associated with coronary artery disease, who were treated with S ...
Ivan V, Chopei, Ksenia I, Chubirko, Mykhailo V, Bychko, Mykhaylo M, Hechko, Antonina V, Kedyk, Ivan I, Kogutych   +5 more
openaire   +2 more sources

Effects of S-Amlodipine in the Management of Hypertension in Mongolian Patients

Cardiology and Angiology: An International Journal, 2022
Objective: To evaluate the efficacy and safety of S-Amlodipine in patients suffering from hypertension. Materials and Methods: A multicenter, prospective, open-label, non-comparative, clinical trial was conducted on 364 patients with hypertension in Mongolia.
Namita Anchan, Shrikant Patil, Orgil Sengeragchaa, Javzankhuu Amarsanaa, Manish Maladkar   +4 more
openaire   +1 more source

The Effects of Amlodipine and S(-)-Amlodipine on Vascular Endothelial Function in Patients With Hypertension [PDF]

American Journal of Hypertension, 2013
Amlodipine has been shown to improve vascular endothelial function in hypertensive patients, but whether S(-)-amlodipine has a similar effect remains controversial. This study compared the effects of amlodipine and S(-)-amlodipine on vascular endothelial function in hypertensive patients and investigated relevant mechanisms of action in cell culture ...
Yuquan, He, Daoyuan, Si, Chunyan, Yang, Lujia, Ni, Bing, Li, Mei, Ding, Ping, Yang   +6 more
openaire   +2 more sources